MA29731B1 - Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne - Google Patents

Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne

Info

Publication number
MA29731B1
MA29731B1 MA30618A MA30618A MA29731B1 MA 29731 B1 MA29731 B1 MA 29731B1 MA 30618 A MA30618 A MA 30618A MA 30618 A MA30618 A MA 30618A MA 29731 B1 MA29731 B1 MA 29731B1
Authority
MA
Morocco
Prior art keywords
diseases
tyroidian
receptor agonists
hormone receptor
pyridazinone derivatives
Prior art date
Application number
MA30618A
Other languages
English (en)
Inventor
Nancy-Ellen Haynes
Denis John Kertesz
Sherrie Lynn Pietranico-Cole
Yimin Qian
Nathan Robert Scott
Sung-Sau So
Kshitij Chhabilbhai Thakkar
Jefferson Wright Tilley
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA29731B1 publication Critical patent/MA29731B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/18—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSÉS DE LA FORMULE (I) ET DES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CES DERNIERS, LES SUBSTITUANTS ÉTANT TELS QUE MENTIONNÉS DANS LA DESCRIPTION. LES COMPOSÉS PRÉCITÉS, ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, SONT UTILISÉS DANS LE TRAITEMENT DE MALADIES TELLES QUE L'OBÉSITÉ, L'HYPERLIPIDÉMIE, L'HYPERCHOLESTÉROLÉMIE ET LE DIABÈTE ET AUTRES AFFECTIONS ET MALADIES LIÉES, ET PEUVENT ÊTRE UTILISÉS POUR D'AUTRES MALADIES TELLES QUE LA STÉATO-HÉPATITE NON ALCOOLIQUE (NASH), L'ATHÉROSCLÉROSE, LES MALADIES CARDIOVASCULAIRES, L'HYPOTHYROÏDIE, LE CANCER DE LA THYROÏDE ET AUTRES AFFECTIONS ET MALADIES LIÉES.
MA30618A 2005-07-21 2008-02-01 Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne MA29731B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70121505P 2005-07-21 2005-07-21

Publications (1)

Publication Number Publication Date
MA29731B1 true MA29731B1 (fr) 2008-09-01

Family

ID=37114368

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30618A MA29731B1 (fr) 2005-07-21 2008-02-01 Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne

Country Status (31)

Country Link
US (3) US7452882B2 (fr)
EP (1) EP1919878B1 (fr)
JP (1) JP5000649B2 (fr)
KR (1) KR100965006B1 (fr)
CN (1) CN101228135B (fr)
AR (1) AR054848A1 (fr)
AT (1) ATE480524T1 (fr)
AU (1) AU2006271721C1 (fr)
BR (1) BRPI0613754B8 (fr)
CA (1) CA2614529C (fr)
CR (1) CR9644A (fr)
CY (1) CY1110929T1 (fr)
DE (1) DE602006016821D1 (fr)
DK (1) DK1919878T3 (fr)
EC (1) ECSP088120A (fr)
ES (1) ES2349131T3 (fr)
HR (1) HRP20100633T1 (fr)
IL (1) IL188476A (fr)
MA (1) MA29731B1 (fr)
MX (1) MX2008000818A (fr)
MY (1) MY142861A (fr)
NO (1) NO340679B1 (fr)
NZ (1) NZ565190A (fr)
PL (1) PL1919878T3 (fr)
PT (1) PT1919878E (fr)
RS (1) RS51639B (fr)
RU (1) RU2379295C2 (fr)
TW (1) TWI330636B (fr)
UA (1) UA88104C2 (fr)
WO (1) WO2007009913A1 (fr)
ZA (1) ZA200800405B (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128058A2 (fr) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Composes thyromimetiques utilises pour traiter les maladies hepatiques graisseuses
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
EP1604988A1 (fr) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Dérivés de pyridazinone, méthodes de leur préparation et leur utilisation comme pharmaceutiques
PL1919878T3 (pl) 2005-07-21 2011-03-31 Hoffmann La Roche Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
WO2008133141A1 (fr) * 2007-04-24 2008-11-06 Toyo Boseki Kabushiki Kaisha Protéine recombinante d'osmotine, son procédé de fabrication et son utilisation
RS51501B (sr) 2007-06-06 2011-04-30 Torrent Pharmaceuticals Ltd Nova jedinjenja
US8076334B2 (en) * 2007-09-20 2011-12-13 Hoffmann-La Roche Inc. Prodrugs of thyroid hormone analogs
ES2524787T3 (es) 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
KR100981781B1 (ko) 2008-02-29 2010-09-10 재단법인 한국원자력의학원 방사선 치료용 콜리메이터 장치 및 그 장치를 이용한방사선 치료장치
WO2010003624A2 (fr) 2008-07-09 2010-01-14 Sanofi-Aventis Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
TWI534144B (zh) * 2009-04-20 2016-05-21 田邊三菱製藥股份有限公司 甲狀腺荷爾蒙β受體作動藥
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
JP5847533B2 (ja) * 2010-10-19 2016-01-27 田辺三菱製薬株式会社 新規甲状腺ホルモンβ受容体作動薬
EP2683705B1 (fr) 2011-03-08 2015-04-22 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
LT4406594T (lt) * 2012-09-17 2025-12-29 Madrigal Pharmaceuticals, Inc. Skydliaukės hormono analogai
CN105272927A (zh) * 2015-11-17 2016-01-27 华中药业股份有限公司 一种制备氯氮卓的新方法
IL266054B2 (en) 2016-10-18 2023-10-01 Madrigal Pharmaceuticals Inc Methods for treating liver disorders or lipid disorders using a THR-BETA agonist
CA3044059A1 (fr) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Methodes de traitement de glycogenose
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
CA3075877A1 (fr) 2017-09-14 2019-03-21 Riken Procede de production de tissus retiniens
CN109574995B (zh) * 2018-01-23 2020-07-24 深圳市塔吉瑞生物医药有限公司 取代的哒嗪酮化合物
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
HUE059420T2 (hu) 2018-04-16 2022-11-28 Ioulia Tseti Egy tiroid hormont tartalmazó gyógyászati száraz por készítmény inhalálásra
CN111801324B (zh) 2018-06-12 2021-10-22 四川海思科制药有限公司 甲状腺激素受体激动剂及其用途
CN110627773B (zh) * 2018-06-22 2021-03-19 海创药业股份有限公司 氘代mgl-3196化合物及其用途
TW202019914A (zh) * 2018-07-02 2020-06-01 美商瑪德瑞高製藥公司 ２-（３，５-二氯-４-（（５-異丙基-６-側氧基-１，６-二氫噠嗪-３-基）氧）苯基）-３，５-二側氧基-２，３，４，５-四氫-１，２，４-三嗪-６-腈之固體型式
CA3110520A1 (fr) * 2018-08-24 2020-02-27 Terns, Inc. Composes agonistes des recepteurs beta des hormones thyroidiennes
JP2022500366A (ja) * 2018-09-06 2022-01-04 ガルメド リサーチ アンド ディベロップメント リミテッド 肝疾患治療のための併用療法
TWI840423B (zh) * 2018-10-12 2024-05-01 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
US12391677B2 (en) * 2018-10-12 2025-08-19 InventisBio Co., Ltd. Thyroid hormone receptor agonists
WO2020117962A1 (fr) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions pour le traitement de la fibrose et de l'inflammation
CN111320609A (zh) 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111592528A (zh) * 2019-02-20 2020-08-28 苏州泽璟生物制药股份有限公司 氘代的哒嗪酮及其衍生物和药物组合物
US12338206B2 (en) 2019-02-21 2025-06-24 Nanjing Ruijie Pharma Co., Ltd. Compounds and their uses as thyroid hormone receptor agonists
KR20210138639A (ko) 2019-03-13 2021-11-19 다이니뽄 스미토모 세이야쿠 가부시키가이샤 이식용 신경 망막의 품질을 평가하는 방법 및 이식용 신경 망막 시트
GEP20247637B (en) * 2019-05-08 2024-06-25 Aligos Therapeutics Inc Modulators of thr-b and methods of use thereof
WO2020228577A1 (fr) * 2019-05-10 2020-11-19 深圳微芯生物科技股份有限公司 Dérivé de pyridazinone et son utilisation
CN114174282A (zh) * 2019-05-29 2022-03-11 南京明德新药研发有限公司 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
AU2020334943A1 (en) 2019-08-19 2022-03-10 Hepagene Therapeutics (HK) Limited Heterocyclic THR-β receptor agonist compound and preparation method and use therefor
CN112409340B (zh) 2019-08-21 2022-03-18 海创药业股份有限公司 卤素取代的苯醚类化合物及其用途
AU2020336272A1 (en) 2019-08-23 2022-04-14 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CN112442013B (zh) * 2019-09-04 2022-07-26 广东东阳光药业有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
CN114375193B (zh) * 2019-09-12 2024-05-14 拓臻制药公司 甲状腺激素受体β激动剂化合物
WO2021057791A1 (fr) * 2019-09-24 2021-04-01 广东东阳光药业有限公司 Composé chimique en tant qu'agoniste du récepteur bêta de l'hormone thyroïdienne et son utilisation
CN112707892A (zh) * 2019-10-24 2021-04-27 苏州泽璟生物制药股份有限公司 哒嗪酮或哒嗪类化合物及其衍生物和药物组合物
EP4083024A4 (fr) * 2019-11-26 2023-11-01 KPC Pharmaceuticals, Inc. Composé de 1,2,4-triazine-3,5-dione, son procédé de préparation et son utilisation
WO2021129465A1 (fr) * 2019-12-26 2021-07-01 苏州科睿思制药有限公司 Cristal de resmétirom, son procédé de préparation et ses utilisations
CN113045551B (zh) * 2019-12-27 2024-07-09 广东东阳光药业股份有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
EP4090652A1 (fr) 2020-01-13 2022-11-23 Eccogene (Shanghai) Co., Ltd. Triazinones substituées en tant qu'agonistes du récepteur de l'hormone thyroïdienne
CN113278013B (zh) * 2020-02-20 2022-09-23 昆药集团股份有限公司 2,6-二取代的1,2,4-三嗪-3,5-二酮化合物及其制备方法和应用
CN113698388B (zh) * 2020-05-20 2022-11-22 江苏恒瑞医药股份有限公司 6-氧代-1,6-二氢吡啶类衍生物、其制备方法及其在医药上的应用
US20230257367A1 (en) 2020-06-02 2023-08-17 Chengdu Kanghong Pharmaceutical Co., Ltd. Novel thyroid hormone beta receptor agonist
CN116056709A (zh) * 2020-08-27 2023-05-02 益方生物科技(上海)股份有限公司 哒嗪酮化合物
WO2022053028A1 (fr) * 2020-09-10 2022-03-17 南京明德新药研发有限公司 Composé de 1,2,4-triazine-3,5-(2h,4h)-dicétone et son utilisation
US12595254B2 (en) 2020-09-10 2026-04-07 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystal form of Resmetirom, preparation method therefor, and use thereof
CA3194226A1 (fr) 2020-09-11 2022-03-17 Riken Complexe contenant des agregats cellulaires contenant une retine neuronale, matrice et procede de fabrication
EP4201428A4 (fr) 2020-09-11 2024-09-11 Sumitomo Pharma Co., Ltd. Milieu pour tissu destiné à la transplantation
WO2022068915A1 (fr) * 2020-09-30 2022-04-07 江苏恒瑞医药股份有限公司 Dérivé de 6-oxo-1,6-dihydropyridazine, son procédé de préparation et son application en médecine
WO2022086894A1 (fr) 2020-10-19 2022-04-28 Teva Pharmaceuticals International Gmbh Formes solides de resmetirom
IL301821A (en) * 2020-10-23 2023-06-01 Madrigal Pharmaceuticals Inc Process for the preparation of 6-(4-nitro-phenoxy)-2h-pyridazin-3-one and 6-(4-amino-phenoxy)-2h-pyridazin-3-one derivatives as intermediates of thyroid hormone analogues
CN114437042A (zh) * 2020-11-03 2022-05-06 深圳微芯生物科技股份有限公司 酞嗪类化合物的晶型及其制备方法
WO2022099049A1 (fr) * 2020-11-06 2022-05-12 Aligos Therapeutics, Inc. Dérivés de pyridazinone en tant qu'agonistes du récepteur thyroïdien et leurs utilisations
JP2023550597A (ja) * 2020-11-06 2023-12-04 アリゴス セラピューティクス，インコーポレーテッド 甲状腺ホルモン受容体ベータ（ＴＲ－β）アゴニストとしての二環式ピリダジノン
CN112645936B (zh) 2020-12-17 2022-03-01 山东第一医科大学(山东省医学科学院) 取代的哒嗪酮类化合物及其用途
CN114685450A (zh) 2020-12-30 2022-07-01 昆药集团股份有限公司 2-吡啶酮类衍生物及其制备方法和在医药上的应用
CN114907327A (zh) * 2021-02-10 2022-08-16 杭州领业医药科技有限公司 Resmetirom的晶型及其制备方法和用途
CN115073429A (zh) * 2021-03-15 2022-09-20 昆药集团股份有限公司 一种1，2，4-三嗪-3，5-二酮类化合物的盐型、晶型及其制备方法
CN116063296B (zh) * 2021-11-02 2025-08-19 凯思凯迪（上海）医药科技有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
WO2023090427A1 (fr) 2021-11-19 2023-05-25 国立研究開発法人理化学研究所 Procédé de production de tissu rétinien en forme de feuille
WO2023171556A1 (fr) * 2022-03-10 2023-09-14 積水化学工業株式会社 Agent inhibiteur d'infection virale, produit inhibiteur d'infection virale, matériau de revêtement inhibiteur d'infection virale, et composition de résine
CN116836158A (zh) * 2022-03-23 2023-10-03 凯思凯迪（上海）医药科技有限公司 一种作为甲状腺激素β受体激动剂的化合物及其用途
WO2024084491A1 (fr) * 2022-10-21 2024-04-25 Mehta Nilesh Vipinchandra Procédé de synthèse de res metirom et de ses intermédiaires
CN118146217A (zh) 2022-12-07 2024-06-07 昆药集团股份有限公司 一种甲状腺激素β受体激动剂、晶型、制备方法和用途
CN115650928B (zh) * 2022-12-28 2023-03-31 凯思凯旭(上海)医药科技有限公司 一种多环类甲状腺激素β受体激动剂及其用途
WO2024141076A1 (fr) * 2022-12-29 2024-07-04 Gannex Pharma Co., Ltd. Promédicaments pour analogues d'hormones thyroïdiennes et leur procédé de fabrication et d'utilisation
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
CN116768802B (zh) * 2023-05-25 2025-11-21 杭州科巢生物科技有限公司 一种瑞司美替罗的合成方法
WO2025011259A1 (fr) * 2023-07-07 2025-01-16 苏州科睿思制药有限公司 Forme cristalline de resmetirom, son procédé de préparation et son utilisation
CN117263870B (zh) * 2023-09-21 2026-02-06 江西同和药业股份有限公司 一种Resmetirom关键中间体III的制备方法
WO2025083699A2 (fr) 2023-10-16 2025-04-24 Cipla Limited Polymorphes de resmétirom et procédé associé
WO2025171032A1 (fr) 2024-02-06 2025-08-14 Madrigal Pharmaceuticals, Inc. Méthodes de traitement d'une stéatose hépatique
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
WO2025191457A1 (fr) * 2024-03-13 2025-09-18 Morepen Laboratories Limited Procédé de préparation d'un dérivé de pyridazinone
WO2025230749A1 (fr) 2024-05-03 2025-11-06 Aligos Therapeutics, Inc. Procédés de préparation de 6-amino-2-[3,5-dichloro-4-[(5-isopropyl-6-oxo -1 h-pyridazin-3-yl) oxy] phényl]-4 h-1, 2, 4-tri-azine-3, 5-dione
CN119868564A (zh) * 2024-09-30 2025-04-25 海创药业股份有限公司 一种用于预防和/或治疗肥胖的联合用药物
WO2026074443A1 (fr) 2024-10-01 2026-04-09 Assia Chemical Industries Ltd. Formes solides de resmétirom
CN119798230B (zh) * 2025-03-13 2025-06-27 中国药科大学 吲哚酮类化合物及其在治疗急慢性肝病与促进组织修复中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582842A (en) * 1981-02-25 1986-04-15 Merck & Co., Inc. Anti-asthmatic 6H-dibenz-[b,e] [1,4]oxathiepin derivatives, compositions, and method of use therefor
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
AU4440596A (en) 1995-02-10 1996-08-22 Smithkline Beecham Corporation Use of hcp SH2 specific compounds to enhance erythropoiesis
PT832067E (pt) 1995-06-06 2003-10-31 Pfizer Processo para a conversao de 2,4-dicloropiridinas a 2-ariloxi-4-cloropiridinas
AU6480796A (en) 1995-06-30 1997-02-05 Smithkline Beecham Corporation Use of stat 6 sh2 domain specific compounds to treat allergic reactions
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
GB9713739D0 (en) * 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
CN1142148C (zh) * 1997-11-19 2004-03-17 兴和株式会社 新颖的哒嗪衍生物和含有其作为有效成分的药物
AR023659A1 (es) 1998-09-18 2002-09-04 Vertex Pharma Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos
EA004229B1 (ru) * 1999-03-01 2004-02-26 Пфайзер Продактс Инк. Оксаминовые кислоты и их производные в качестве лигандов тиреоидных рецепторов
WO2002051805A1 (fr) * 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Derives de l'indole utilises comme ligands de recepteurs de la thyroide
EP1358175A2 (fr) * 2001-02-08 2003-11-05 Karo Bio Ab Nouveaux ligands de recepteurs thyroidiens
EP1236720B1 (fr) * 2001-02-28 2005-06-15 Pfizer Products Inc. Derives de sulfonyl-pyridazinone comme inhibiteurs de reductase d'aldose
BRPI0408704A (pt) * 2003-03-24 2006-03-07 Hoffmann La Roche benzil-piridazinonas como inibidores de transcriptase reversa
CN1882327A (zh) 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2005090317A1 (fr) * 2004-03-23 2005-09-29 F.Hoffmann-La Roche Ag Derives benzyl-pyridazinone servant d'inhibiteurs d'une transcriptase inverse non nucleosidique
PL1919878T3 (pl) 2005-07-21 2011-03-31 Hoffmann La Roche Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy

Also Published As

Publication number Publication date
IL188476A0 (en) 2008-04-13
USRE46024E1 (en) 2016-06-07
RU2379295C2 (ru) 2010-01-20
EP1919878A1 (fr) 2008-05-14
IL188476A (en) 2011-10-31
HK1115129A1 (en) 2008-11-21
ATE480524T1 (de) 2010-09-15
EP1919878B1 (fr) 2010-09-08
PT1919878E (pt) 2010-11-02
DK1919878T3 (da) 2010-10-25
KR20080019297A (ko) 2008-03-03
KR100965006B1 (ko) 2010-06-21
RS51639B (sr) 2011-10-31
BRPI0613754B8 (pt) 2021-05-25
JP5000649B2 (ja) 2012-08-15
CN101228135B (zh) 2011-08-31
CN101228135A (zh) 2008-07-23
MY142861A (en) 2011-01-14
ECSP088120A (es) 2008-02-20
TW200745052A (en) 2007-12-16
DE602006016821D1 (de) 2010-10-21
BRPI0613754A2 (pt) 2011-02-08
US7452882B2 (en) 2008-11-18
UA88104C2 (ru) 2009-09-10
CA2614529A1 (fr) 2007-01-25
JP2009501759A (ja) 2009-01-22
AU2006271721A1 (en) 2007-01-25
NO20080058L (no) 2008-04-18
BRPI0613754B1 (pt) 2021-03-16
HRP20100633T1 (hr) 2011-01-31
MX2008000818A (es) 2008-03-18
ZA200800405B (en) 2008-12-31
AU2006271721B2 (en) 2010-06-17
PL1919878T3 (pl) 2011-03-31
US20070032494A1 (en) 2007-02-08
AR054848A1 (es) 2007-07-18
RU2008106058A (ru) 2009-08-27
ES2349131T3 (es) 2010-12-28
CR9644A (es) 2008-02-20
US7807674B2 (en) 2010-10-05
NO340679B1 (no) 2017-05-29
US20090005383A1 (en) 2009-01-01
CY1110929T1 (el) 2015-06-10
TWI330636B (en) 2010-09-21
CA2614529C (fr) 2011-06-28
NZ565190A (en) 2010-02-26
WO2007009913A1 (fr) 2007-01-25
AU2006271721C1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
MA29731B1 (fr) Derives de pyridazinone utilises comme agonistes du recepteur de l'hormone tyroïdienne
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA29909B1 (fr) Derives de pyridazine
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
MA28747B1 (fr) Dérivés de pyridine
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA27728A1 (fr) Antagonistes des recepteurs de cgrp
MA30602B1 (fr) Modulateurs du metabolisme, et traitement de troubles au moyen de ces modulateurs
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA27774A1 (fr) Inhibiteurs de phosphatidylinositol 3-kinase
MA33056B1 (fr) Composition pharmaceutique solide comprenant de l'amlodipine et du losartan et son procede de fabrication
MA31373B1 (fr) Composes amino-heterocycliques
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA27883A1 (fr) Derives de pyrido [2,1-a] isoquinoline utilises comme inhibiteurs de dpp-iv
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
TN2009000450A1 (fr) Derives de pyridine
MA29926B1 (fr) Derives de pyrazine
MA33219B1 (fr) Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
MA30289B1 (fr) Dérivés d'amines
TNSN98203A1 (fr) Derives de thienopyrimidine et tienopyridine utiles comme agents anticancereux, et compositions les contenant
MA31754B1 (fr) Cis-imidazolines chirales